Biofil Chemicals & Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025.

Results View source PDF Explain this filing

BIOFILCHEM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.8%Reaction day

₹39.71

prior close

₹39.36

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.1%-1.7% vs market

Pharmaceuticals peers, median of 157sector+0.0%-1.8% vs sector

On the reaction day the stock moved 1.7 pts less than Nifty Microcap 250 and 1.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.0

10m

+0.0

15m

+0.0

30m

+0.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.8-0.1-1.7+0.0-1.8

Next day

+0.2+0.5-0.3-0.1+0.3

-2.5-0.3-2.2-0.9-1.6

-1.8-0.5-1.3-1.3-0.4

-1.8-0.8-1.0-1.6-0.2

-3.5-2.3-1.2-2.3-1.2

-8.0-2.8-5.2-2.9-5.1

15d

-11.9-4.9-7.0-3.1-8.8

-11.9-4.7-7.1-4.3-7.6

-15.3-7.7-7.5-5.6-9.6

-14.4-7.8-6.5-10.3-4.1

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Biofil Chemicals & Pharmaceuticals Limited has submitted its financial results for the quarter/half-year ended September 30, 2025, to the NSE. The company has fulfilled its listing obligation by filing these results with the exchange on time. No actual financial figures, revenue numbers, or profit details were provided in the announcement, so the performance cannot be assessed from this filing alone. Shareholders would need to review the full financial results document for specific numbers.

Likely market impact

This is a routine regulatory filing with no immediate impact on shareholders or stock price. Investors should look at the actual numbers in the detailed results to gauge the company's Q2/H1 FY26 performance.